About US
Contact us
-
Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey findsThe path to approval was long and winding for a new class of medicines calledhypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. And even afterGSK clinched regulatory victory earlier thi2023/2/17
-
Eli Lilly's employment decisions under fire once again as sales rep lodges age discrimination claimNot even six months after the U.S. Equal Employment Opportunity Commission sued Eli Lilly over alleged age bias, the company is at the center of another discrimination lawsuit. Monica Ric2023/2/15
-
GSK's unusual Jemperli expansion plan wins FDA panel backing—with a twistDuring a heated discussion around a potential GSK application for Jemperli in a rare cancer type, a panel of the FDA's external advisers largely took the middle ground between the company and the reg2023/2/15
-
Nearing FDA approval anniversary, Phathom gets more bad news on Voquezna impuritiesAs Phathom Pharmaceuticals approaches the one-year anniversary ofVoquezna's FDA approval to treat Helicobacter pylori infection, the regulatory blows keep coming. Late this week, Phathom2023/2/13
-
Roche's Vabysmo shows an edge over Regeneron's Eylea in retina dryingNew data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO)showsthat more patients on Vabysmo had an absence of blood vessel leakage in2023/2/13
-
ABPI president, a Novo Nordisk exec, steps down after company's code breachesAfter Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national organizat2023/2/9
-
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned downIn a tight BCMA CAR-T race, Bristol Myers Squibb has delivered the drug class’s first randomized trial win in multiple myeloma. But the detailed data, recently rejected by the American Society of Hem2023/2/9
-
Regeneron wins another FDA nod for powerhouse Eylea despite trial flopsFour years afterscoringan approval to treat diabetic retinopathy—a disease that strikes more than a third of those with diabetes and is the primary cause of blindness in the U.S.—Regeneron’s Eylea ha2023/2/7
-
Looking forward to Humira biosimilar launch, Teva leans on Ajovy and Austedo as revenues sinkTeva's new CEO Richard Francis has his work cut out as the company seeks to recover from a revenue slide. Thanks to declines for several of its offerings, Tevaglobalsales slipped 5% year2023/2/7
-
Amgen aims to make the most of Amjevita's head start amid broader biosim lull, Lumakras missThe biosimilars business is tough to conquer, but Amgenhopes its newest launch can help it overcome a slowdown for its older copycat products and a lull for new cancer med Lumakras. Boast2023/2/3